DWP
AQST icon

Daymark Wealth Partners’s Aquestive Therapeutics AQST Stock Holding History

Daymark Wealth Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Buy
38,278
+3,000
+9% +$12.2K 0.01% 717
2025
Q4 		$228K Buy
35,278
+10,000
+40% +$62.3K 0.01% 560
2025
Q3 		$141K Buy
25,278
+7,778
+44% +$33.6K ﹤0.01% 594
2025
Q2 		$57.9K Buy
+17,500
New +$50.2K ﹤0.01% 558

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Daymark Wealth Partners's AQST Position: Q1 2026 in Review

Daymark Wealth Partners increased its Aquestive Therapeutics (AQST) stake by 8.5% in Q1 2026, buying an estimated $12.2K and bringing the position to 38,278 shares worth $159K. The position accounts for 0.01% of the portfolio, ranked #717.

Daymark Wealth Partners first reported a position in AQST in Q2 2025 and has held it in 4 quarters since. The position peaked at $228K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Daymark Wealth Partners held 38,278 shares of Aquestive Therapeutics worth $159K as of Q1 2026.
  • Daymark Wealth Partners bought 3,000 Aquestive Therapeutics shares in Q1 2026, an estimated $12.2K.
  • Aquestive Therapeutics made up 0.01% of Daymark Wealth Partners's portfolio in Q1 2026, its #717 holding.
  • Daymark Wealth Partners first reported a position in Aquestive Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Daymark Wealth Partners's Aquestive Therapeutics position peaked at $228K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Daymark Wealth Partners's 13F filing for Q1 2026, filed 11 May 2026.